Full Title
A Phase I Dose Escalation Trial of Compartmental Radioimmunotherapy (cRIT) Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients with Recurrent or Refractory B7H3 Expressing Primary or Metastatic CNS TumorsPurpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Sameer Farouk Sait’s office at 212-639-3449.
Protocol
26-097
Phase
Phase I (phase 1)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators